Related Experiment Video

Updated: May 6, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.6K

Clinical application of high-throughput genomic technologies for treatment selection in breast cancer

Aaron R Hansen, Philippe L Bedard

    Breast Cancer Research : BCR
    |October 19, 2013
    PubMed

    Insights

    Genomic sequencing reveals breast cancer driver mutations for targeted therapies. Molecular screening programs now guide treatment decisions for advanced breast cancer patients.

    Area of Science:

    • Genomics
    • Oncology
    • Molecular Diagnostics

    Background:

    • Large-scale genomic studies are characterizing the breast cancer genome.
    • Next-generation sequencing has identified key driver mutations.
    • These mutations represent potential therapeutic targets.

    Purpose of the Study:

    • To provide an overview of recent molecular insights in breast cancer.
    • To discuss actionable somatic alterations and detection technologies.
    • To highlight molecular screening programs for advanced breast cancer.

    Main Methods:

    • Review of large-scale collaborative initiatives and landmark studies.
    • Analysis of high-throughput genomic technologies in clinical diagnostics.
    • Examination of institutional and regional molecular screening programs.

    Main Results:

    • Identification of infrequent but actionable driver mutations in breast cancer.
    • Advancements in high-throughput genomic platforms for clinical use.
    • Implementation of molecular screening programs for advanced cancers.

    Conclusions:

    • Genomic characterization has unveiled critical therapeutic targets in breast cancer.
    • Molecular screening is increasingly informing clinical decision-making for advanced disease.
    • Technological progress facilitates the detection and targeting of somatic alterations.

    More Related Videos

    Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

    Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

    Published on: April 11, 2016

    14.0K
    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

    Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

    Published on: December 5, 2017

    12.1K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.1K
    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    129
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    84